Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases insulin levels.
Related Posts
Battling for Budget Bookings, Discount Airlines Offer ‘Poor Man’s First Class’
Spirit and Frontier bundle amenities such as alcohol, Wi-Fi and bigger seats as they weather financial turbulence.
European Rocket Launch Takes Aim at SpaceX
After years of delays, Europe will test launch Tuesday a new rocket that officials hope will help diminish the U.S. company’s dominance.
UniCredit Boosts Revenue Outlook, Dividends
UniCredit raised its revenue guidance for the year and said it would pay out around €1.4 billion in interim dividends, after the Italian bank posted […]